MKRN2在通过宿主微环境和巨细胞M1到M2开关调节瘤生长中的新型作用
Jian-Ge Qiu1, Peng Sang2, Feng-Mei Zhou3
1Department of Radiology, Department of Clinical Research and Translational Medicine, The Third Affiliated Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, 450002, China; State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, China.
马科林-2 (MKRN2) 通过控制巨细胞极化和炎症来调节瘤微环境 (TME). 失去MKRN2会加速瘤的生长,并恶化患者的生存率,突出其作为癌症生物标志物和治疗点的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 瘤微环境 (TME) 对癌症进展至关重要,但其免疫抑制调节者尚未完全理解.
- 马科林-2 (MKRN2) 被确定为一种影响TME的新型因素.
- 了解MKRN2的作用对于开发新的癌症疗法至关重要.
研究的目的:
- 研究马科林-2 (MKRN2) 在调节瘤微环境 (TME) 中的作用.
- 探索MKRN2对免疫细胞组成,巨细胞两极分化和癌症进展的影响.
- 确定MKRN2调节的机制及其作为预后生物标志物和治疗点的潜力.
主要方法:
- 利用基因工程小鼠模型 (MKRN2淘汰) 和人类临床数据.
- 分析了免疫细胞组成,重点关注瘤相关巨细胞 (TAMs).
- 调查了MKRN2的表观遗传和转录后调节,以及其作为针对NF-κB p65.5.的E3泛基因结合酶的分子功能.
主要成果:
- 缺乏MKRN2加速了瘤的生长,并促进了M2巨细胞在TME中的极化.
- 低MKRN2表达与晚期癌症相相关,并且在多种恶性瘤中降低了患者的存活率.
- 通过促进物甲基化和miR-582-5p抑制发生MKRN2下调;MKRN2降解NF-κB p65,抑制炎症信号传递.
结论:
- MKRN2通过控制巨细胞极化和NF-κB/COX2信号传递,是免疫抑制性TME形成的关键调节者.
- MKRN2通过抑制增殖,迁移和入侵而起瘤抑制作用.
- MKRN2具有作为癌症免疫治疗的预后生物标志物和治疗点的潜力.
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Tumor Microenvironment
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle
PI3K/mTOR/AKT Signaling Pathway


